Ayurcann Holdings Corp

Healthcare US AYURF

0.0188USD
-(-%)

Last update at 2025-06-12T13:30:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.010.12
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap4.17M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.16780M
  • Revenue TTM25.16M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM 2.22M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -5.30713M -1.72779M 0.06M -0.23694M -0.22282M
Minority interest - - - - -
Net income -5.30713M -3.08791M -0.27836M -0.23694M -0.22282M
Selling general administrative 8.22M 5.51M 2.46M 0.21M 0.20M
Selling and marketing expenses - - - - -
Gross profit 3.68M 3.92M 4.63M - -
Reconciled depreciation 0.78M 0.32M 0.28M - -
Ebit - -3.33221M 2.16M -0.05822M -1.07476M
Ebitda - -1.31585M 0.65M -0.24478M -0.23996M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -4.99108M -1.59912M 2.16M -0.24478M -0.23996M
Other operating expenses - - - - 0.38M
Interest expense 0.03M 0.09M 0.32M 0.00000M 0.00000M
Tax provision 0.00000M -0.33545M 0.34M - -
Interest income - - - - -
Net interest income -0.03019M -0.09115M -0.31518M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.33545M 0.34M - -
Total revenue 12.49M 11.08M 7.63M 0.00000M 0.00000M
Total operating expenses 17.48M 12.68M 5.47M 0.24M 0.24M
Cost of revenue 8.81M 7.17M 3.01M - -
Total other income expense net -0.28585M -0.03753M -1.78704M 0.00784M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -5.30713M -1.39234M -0.27836M -0.23694M -0.22282M
Net income applicable to common shares - -3.08791M -0.27836M -0.60456M -1.05717M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 14.85M 12.73M 7.28M 6.68M 1.13M
Intangible assets 1.75M 2.30M - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 14.32M 10.04M 2.39M 1.93M 0.02M
Total stockholder equity 0.53M 2.69M 4.89M 4.75M 1.11M
Deferred long term liab - - - - -
Other current liab - - - 0.34M 0.15M
Common stock - - 8.05M 5.79M 1.54M
Capital stock 12.95M 11.16M 8.05M 5.79M 7.94M
Retained earnings -14.37903M -10.41129M -5.10416M -2.01625M -1.73789M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.39M 0.97M 1.35M 0.73M 1.12M
Cash and equivalents - - - - -
Total current liabilities 13.60M 9.98M 2.17M 1.57M 0.54M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt 0.04M - - - -
Short long term debt total - - - - -
Other stockholder equity - - 0.94M 0.13M 0.04M
Property plant equipment - - 1.19M 1.25M 0.86M
Total current assets 11.50M 9.27M 6.09M 5.43M 0.67M
Long term investments - - - - -
Net tangible assets - - 4.89M 4.75M 0.66M
Short term investments - - - - -
Net receivables 5.24M 4.84M 1.54M 2.08M 0.35M
Long term debt 0.13M - 0.04M 0.04M -
Inventory 5.36M 3.28M 2.95M 2.32M 0.28M
Accounts payable 4.17M 2.07M 0.91M 1.00M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 3.36M 3.46M 1.19M 1.25M 0.00000M
Capital lease obligations 0.73M 0.18M 0.32M 0.44M -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.29738M -0.26262M 0.36M - -
Change to liabilities - 0.91M 0.95M 0.08M 0.05M
Total cashflows from investing activities - -0.26262M 0.36M -0.40115M -0.28258M
Net borrowings - -0.18469M -0.27449M 0.09M 0.09M
Total cash from financing activities 0.19M 0.94M 0.54M 0.25M 0.92M
Change to operating activities - -0.02411M -0.32035M 0.04M -0.04938M
Net income -5.30713M -3.08791M -0.27836M -0.60456M -1.05717M
Change in cash -0.38286M 0.63M 0.70M -0.47329M 0.50M
Begin period cash flow 1.35M 0.73M 0.02M 1.36M 1.60M
End period cash flow 0.97M 1.35M 0.73M 1.12M 1.36M
Total cash from operating activities -0.27130M -0.05009M -0.19856M -0.31738M -0.13668M
Issuance of capital stock 0.00000M 1.39M 0.77M - 0.00000M
Depreciation 0.78M 0.32M 0.28M 0.18M 0.03M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.32918M -0.63092M -2.03503M -0.28195M -0.28195M
Change to account receivables -3.79307M 0.66M -1.70912M -0.34564M -0.00472M
Sale purchase of stock -0.02047M -0.26066M - - -
Other cashflows from financing activities - - 0.04M -0.00036M -0.00036M
Change to netincome - 2.15M 2.30M 0.10M 0.85M
Capital expenditures 0.30M 0.26M 0.51M 0.40M 0.28M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.34M 0.58M -2.77991M 0.00100M -0.01630M
Stock based compensation 1.53M 2.11M 0.13M - -
Other non cash items 0.03M 0.03M 2.44M - -
Free cash flow -0.56867M -0.31271M -0.70755M -0.23595M -0.23912M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AYURF
Ayurcann Holdings Corp
- -% 0.02 - - 0.16 24.83 0.23 -1.0548
ZTS
Zoetis Inc
-3.2725 1.94% 165.55 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.3 1.12% 26.54 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
4.73 3.60% 136.25 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.12 0.78% 15.27 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. It offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. The company sells product under the Fuego, H&S, and XPLOR brands. Ayurcann Holdings Corp. is headquartered in Pickering, Canada.

Ayurcann Holdings Corp

1080 Brock Road, Pickering, ON, Canada, L1W 3X4

Key Executives

Name Title Year Born
Mr. Igal Sudman Co-Founder, Corp. Sec., CEO & Chairman NA
Mr. Buzaker Roman Co-Founder, Pres, CFO, COO & Director NA
Mr. Raj Virk Head of Quality & Compliance NA
Mr. Igal Sudman Co-Founder, Corporate Secretary, CEO & Chairman NA
Mr. Buzaker Roman Co-Founder, President, COO & Director NA
Mr. Yisroel Zuchter Chief Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.